Un al doilea cancer pulmonar primar, cu masă intracardiacă dezvoltată după malignitate renală – prezentare de caz şi review al literaturii

 Second primary lung cancer with intracardiac mass developed after renal malignancy – case report and literature review

First published: 16 mai 2018

Editorial Group: MEDICHUB MEDIA

DOI: 10.26416/OnHe.43.2.2018.1694


Cardiac metastases are not as rare as considered, their incidence ranging from 2.3% to 18.3%, most commonly from lung cancer. We report the case of a 57-year-old male with a second primary lung cancer in stage IV, with intracardiac mass, developed after a clear renal cell carcinoma. The particular features of the case are discussed, highlighting the important aspects of diagnosis, with reference to known data.

renal cancer, lung cancer, cardiac metastases


Metastazele cardiace nu sunt pe atât de rare pe cât se con­si­de­ră, incidenţa lor fiind cuprinsă între 2,3% şi 18,3%, cel mai ade­sea secundare cancerului pulmonar. Prezentăm cazul unui pa­cient de 57 de ani, cu un al doilea cancer pulmonar primar în stadiul IV, cu o masă intracardiacă, dezvoltată în urma unui car­ci­nom renal cu celule clare. Sunt discutate particularităţile aces­tui caz, subliniind aspectele importante privind diag­nos­ti­cul, referindu-ne şi la datele existente.


Although the outcome of patients diagnosed with renal cell carcinoma (RCC) has improved over the past years, there is a lack of information on the risk of developing a second cancer after RCC.

A population-based study conducted in Norway indicated that nearly 47% of patients with RCC develop a subsequently malignancy, and lungs are a common site of occurence(1,2).

Other studies reported an increased risk of subsequent bladder and prostate cancer for papillary RCC(3,4).

On the other hand, metastatic spreads to the heart are not as rare as considered, their incidence ranging from 2.3% to 18.3%, most commonly from lung cancer through a lymphatic or hematogenous pathway. Furthermore, lung adenocarcinoma has a higher rate of heart metastases (21%) compared to lung squamos cell carcinoma (18.2%)(5,6).

Case presentation

A 57-year-old male, non-smoker, with history of clear renal cell carcinoma (T3N1M0), diagnosed in 2009, for which he had undergone radical nephrectomy on his left side, radiotherapy and received treatment with interferon-alpha, presented to our clinic in May 2014 complaining of progressive dyspnea, productive cough, chest pain and important weight loss (14 kg in two months).

The chest X-ray and the CT scan revealed a tumor mass in the right lower lobe of his lung (6.6/4.5 cm), enlarged mediastinal lymph nodes, and low-density masses in the liver.

The biopsy of a mediastinal lymph node by Carlens mediastinoscopy, and the histopathological findings revealed metastatic adenocarcinoma G3.

Palliative chemotherapy was initiated, the pacient receiving two cycles of carboplatin with vinorelbine. After that, without any symptomatic change, trans­thoracic echocardiography detected in his left ventricular apex a high echogenic mass (1.95/1.08 cm), with no pericardial effusion and no detectable valvular abnormality (Figure 1).

Figure 1. Transthoracic echocardiography imaging
Figure 1. Transthoracic echocardiography imaging

The differential diagnosis included thrombus. However, taking into account that no hipokinesia or left ventricular hyperthrophy was detected and he had a normal ejection fraction, we considered the mass as a cardiac metastasis.

The chemotherapy was changed, the patient receiving one cycle of pemetrexed plus cisplatin. Unfortunately, soon after, the family informed us that he passed away, and no autopsy was performed.


There are two important aspects worth highlighting in our clinical case, namely the development of a second primary lung malignancy after clear RCC, and the appeareance of a solitary cardiac metastasis in the evolution. Clear cell RCC represents the predominant histological subtype of RCC (70-85%), and the development of a second primary cancer after clear cell RCC seems to be more frequent than expected, with lungs as a commun site of occurence(1,2,7).

Therefore, in order to establish an optimal follow-up program for patients with RCC, we should consider the risk of developing other subsequent primary cancer, and promote an effective surveillance for early detection. Regarding cardiac malignancies, most of them are secondary tumors, produced by lung cancer or many other cancers, with a small size, multiple, commonly asymptomatic and indicating widespread metastases. Despite the fact that majority of them are clinically silent, the risk of embolism is high and can lead to death; thus, echocardiography is important in oncologic patients, with or without cardiac symptoms.

To the best of our knowledge, solitary cardiac metastases with intracavitary growth are rare.  

Conflict of interests: The authors declare no conflict of interests.


  1. Beisland C, Talleraas O, Bakke A, et al. Multiple primary malignancies in patients with renal cell carcinoma: a national population-based cohort study. BJU Int. 2006; 97:698–702.  
  2. Chakraborty S, Tarantolo SR, Batra SK, Hauke RJ. Incidence and prognostic significance of second primary cancers in renal cell carcinoma. Am J Clin Oncol. 2013; Apr, 36(2):132-42.
  3. Rabbani F, Reuter VE, Katz J, Russo P. Second primary malignancies associated with renal cell carcinoma: influence of histologic type. Urology. 2000; Sep 1; 56(3):399-403.
  4. Neuzillet Y, Lechevallier E, Coulange C. Renal cancer and second cancer: critical review of the literature. Prog Urol. 2007; Feb, 17(1):35-40.
  5. Bussani R, De-Giorgio F, Abbate A, Silvestri F. Cardiac metastases. J Clin Pathol. 2007; 60:27–34.10.1136/jcp.2005.035105.
  6. Klatt EC, Heitz DR. Cardiac metastases. Cancer. 1990; Mar 15; 65(6):1456-9.
  7. Crumley SM, Divatia M, Truong L, Shen S, Ayala AG, Ro JY. Renal cell carcinoma: Evolving and emerging subtypes. World J Clin Cases. 2013; Dec 16; 1(9): 262–275.

Articole din ediţiile anterioare

REVIEW | Ediţia 1 46 / 2019

Scurtă prezentare a imunoterapiei cu inhibitori PD-1/PD-L1 în cancerul pulmonar fără celulă mică (NSCLC)

Mihaela Albu, Alexandru Grigorescu

Cancerul pulmonar – în special cel fără celule mici (NSCLC), deoarece este mai frecvent – reprezintă o problemă majoră de sănătate, din cauza morta...

27 martie 2019
CASE PRESENTATION | Ediţia 3 / 2016

Carcinomul pulmonar scuamos

Alexandru Grigorescu

Cancerul pulmonar fără celule mici scuamos este unul dintre cancerele care nu are încă un avantaj cert în cadrul terapiei țintite. Deși rezultatele...

07 martie 2017
CASE PRESENTATION | Ediţia 1 58 / 2022

Fighting disease at 83 years old: SARS-CoV-2 survival and response to anti-PD-1 therapy in PD-L1 negative adenocarcinoma of the lung – case report

Maria Nedelcu, Adelina Silvana Dragomir, Elena Adriana Mateianu, Conf. dr. Dana Lucia Stănculeanu

În timpul pandemiei de COVID-19, supra­vie­ţui­rea totală medie a pacienţilor cu cancer pulmonar a scăzut de la 7,9 luni la 6,7 luni. În analiza TE...

25 martie 2022
SHORT REVIEW | Ediţia 4 53 / 2020

Mai există un rol pentru nefrectomia citoreducţională în era terapiilor ţintite şi a imunoterapiei?

Edvina Elena Pîrvu, Irina Niţă, Ştefania Andreea Toma

Renal cell carcinoma (RCC), the most frequent type of kidney cancer, responsible for 5% of oncological diagnosis in men and for 3% in women, repres...

23 decembrie 2020